Skip to main content
Figure 3 | Arthritis Research & Therapy

Figure 3

From: Tissue specific CD4+ T cell priming determines the requirement for interleukin-23 in experimental arthritis

Figure 3

CD4+T cell IL-17 and IFNγ production in spleen and lymph node is inhibited in subcutaneous immunized IL-23p19−/−mice. Spleen and lymph node (LN) were harvested approximately 70 days after rG1/dimethyldioctadecyl ammonium bromide immunization. (A) Representative flow cytometry images of CD4+ T cells from the spleen of BALB/c wild type (WT) and p19−/− intraperitoneal (i.p.; left two panels) and subcutaneous (s.c.; right panels) immunized mice with rG1in adjuvant. (B) Percentage of CD4+ T cells expressing cytokines in spleen after i.p. (left panel) and s.c. (right panels) immunization. (C) Representative flow cytometry images of CD4+ T cells from inguinal LN of BALB/c WT and p19−/− s.c. immunized mice. (D) Percentage of CD4+ T cells expressing cytokines in inguinal LN after s.c. immunization. (E) Concentration (pg/ml) of IFNγ (left panel) and IL-17 (right panel) from CD4+ T cells from WT and p19−/− mice after either i.p. or s.c. immunization and cultured in the presence of rG1and antigen-presenting cells. Supernatants were harvested on day 4 and assayed for cytokines by enzyme-linked immunosorbent assay. Data represent mean ± standard error of the mean (SEM, n =5 mice) from two independent experiments. (F) IFNγ (left panel) and IL-17 (right panel) concentration (pg/ml) from purified CD4+ T cells restimulated in the presence of rG1 and antigen-presenting cells for 4 days. BALB/c WT and p19−/− mice were immunized with rG1 either by i.p. or s.c. route and spleen and inguinal LN were harvested on day 9. Data are the mean ± SEM (n =4 mice) and representative of three independent experiments. *P <0.05. IFN, interferon; IL, interleukin.

Back to article page